Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Brigitte Pégourié-Bandelier"'
Autor:
Alain Delmer, Sylvain Choquet, Maya Ouzegdouh, Marouanne Boubaya, Steven Le Gouill, Olivier Tournilhac, Brigitte Pégourié-Bandelier, Laetitia Souchet, Vincent Levy, Jehan Dupuis, Jerome Tamburini, Jacques Vargaftig, Véronique Leblond
Publikováno v:
American Journal of Hematology. 91:782-786
Waldenstrom's macroglobulinemia is generally treated with alkylating agents, purine analogs and monoclonal antibodies, alone or in combination. We report the outcomes of 82 patients (median age 61 years) treated with the RFC combination. Twenty-five
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a480c4f98efec5787592337b570c92c
https://doi.org/10.1002/ajh.24405
https://doi.org/10.1002/ajh.24405
Autor:
Brigitte Pégourié-Bandelier, Annabelle Merlat-Guitard, Maya Hacini, Ségolène Bisot-Locard, Martine Gardembas-Pain, Dora Bachir, Isabelle Thuret
Publikováno v:
Hematology. 14:315-322
Deferoxamine (DFO) is an iron chelator used to treat iron overload in patients receiving chronic blood transfusions, and is usually administered as overnight subcutaneous infusions. ISOSFER was a prospective, observational, cross-sectional study cond
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12a26154ce87ad6b67d0110b4b2a690f
https://doi.org/10.1179/102453309x12473408860424
https://doi.org/10.1179/102453309x12473408860424
Autor:
Laetitia, Souchet, Vincent, Levy, Maya, Ouzegdouh, Jérôme, Tamburini, Alain, Delmer, Jehan, Dupuis, Steven, Le Gouill, Brigitte, Pégourié-Bandelier, Olivier, Tournilhac, Marouanne, Boubaya, Jacques, Vargaftig, Sylvain, Choquet, Véronique, Leblond
Publikováno v:
American journal of hematology. 91(8)
Waldenstrom's macroglobulinemia is generally treated with alkylating agents, purine analogs and monoclonal antibodies, alone or in combination. We report the outcomes of 82 patients (median age 61 years) treated with the RFC combination. Twenty-five
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7d2f2af55c08a551b9aca56678c2b6a0
https://pubmed.ncbi.nlm.nih.gov/27135784
https://pubmed.ncbi.nlm.nih.gov/27135784
Autor:
Christian Chabannon, Mireille Bost, Jacqueline Leger, Lysiane Molina, Brigitte Pégourié-Bandelier, Daniel Hollard
Publikováno v:
Cancer. 73:3073-3080
Background. Treatment of myelodysplastic syndromes (MDSs) remains unsatisfactory. A limited number of reports provide contradictory information on whether danazol, a synthetic androgen, may be useful in patients with MDS. Methods. Between 1984 and 19
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04c4843ade34e44213a2eca48b464171
https://doi.org/10.1002/1097-0142(19940615)73:12<3073::aid-cncr2820731228>3.0.co
https://doi.org/10.1002/1097-0142(19940615)73:12<3073::aid-cncr2820731228>3.0.co
Autor:
Jacques Vargaftig, Beatrice Mahe, Laetitia Compain, Elisabeth Brottier-Mancini, Brigitte Pégourié-Bandelier, Vincent Levy, Véronique Leblond, Michel Maigre, Agnes Buzyn, Steven Le Guill, Olivier Tournilhac, Richard Delarue, Alain Delmer, Claude Gardin, Jerome Tamburini, Sylvain Choquet
Publikováno v:
Blood. 116:1757-1757
Abstract 1757 Treatment of Waldenström's Macroglobulinemia relies on alkylator agents, nucleoside analogs and/or monoclonal antibody based therapies. We showed previously that combination of fludarabine and cyclophosphamide yields a 78% response ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dbee549a099b7fe10cc90759a970e96a
https://doi.org/10.1182/blood.v116.21.1757.1757
https://doi.org/10.1182/blood.v116.21.1757.1757
Autor:
Martine Raphael, Jacques Vargaftig, Beatrice Mahe, Agnes Buzyn, Sylvain Choquet, Elisabeth Brottier-Mancini, Brigitte Pégourié-Bandelier, Véronique Leblond, Steven Le Gouill, Richard Delarue
Publikováno v:
Blood. 108:4727-4727
Background: Waldenström’s Macroglobulinemia (WM) is a chronic lymphoproliferative disorder characterized by the secretion of a monoclonal IgM. Treatment relies on alkylator-agents based therapy, nucleoside analogs therapy and/or monoclonal antibo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca60e98936505f743e3516cc3ca508dd
https://doi.org/10.1182/blood.v108.11.4727.4727
https://doi.org/10.1182/blood.v108.11.4727.4727